1. Home
  2. DSP vs NMRA Comparison

DSP vs NMRA Comparison

Compare DSP & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viant Technology Inc.

DSP

Viant Technology Inc.

N/A

Current Price

$12.58

Market Cap

279.6M

Sector

Technology

ML Signal

N/A

Logo Neumora Therapeutics Inc.

NMRA

Neumora Therapeutics Inc.

N/A

Current Price

$1.04

Market Cap

302.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
DSP
NMRA
Founded
1999
2019
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
279.6M
302.0M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
DSP
NMRA
Price
$12.58
$1.04
Analyst Decision
Strong Buy
Buy
Analyst Count
8
8
Target Price
$17.81
$7.50
AVG Volume (30 Days)
203.7K
687.0K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
157.14
5.23
EPS
N/A
N/A
Revenue
$344,201,000.00
N/A
Revenue This Year
$20.27
N/A
Revenue Next Year
$16.88
N/A
P/E Ratio
N/A
N/A
Revenue Growth
19.00
N/A
52 Week Low
$8.11
$0.83
52 Week High
$14.80
$3.65

Technical Indicators

Market Signals
Indicator
DSP
NMRA
Relative Strength Index (RSI) 49.45 28.21
Support Level $10.36 $0.83
Resistance Level $13.36 $1.74
Average True Range (ATR) 0.60 0.09
MACD -0.01 -0.03
Stochastic Oscillator 37.89 0.96

Price Performance

Historical Comparison
DSP
NMRA

About DSP Viant Technology Inc.

Viant Technology Inc is an advertising technology company engaged in providing a cloud-based demand-side platform (DSP) for programmatic advertising. The company enables marketers and advertising agencies to plan, buy, and measure digital advertising campaigns across multiple channels, including connected TV, streaming audio, mobile, desktop, and digital out-of-home. Its platform leverages data integrations and proprietary identity solutions to deliver targeted advertising, audience insights, and performance measurement.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Share on Social Networks: